Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Shares of Viatris Inc. VTRS advanced 1.41% to $9.37 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 and ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its ...

Viatris (VTRS) stock dips after its experimental therapy for eyelid inflammation fails a Phase 3 trial. Read more here.

Healthcare company Viatris has been certified as a Great Place to Work® in both Australia and New Zealand, marking the first ...

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

Shares of Viatris Inc. VTRS rallied 3.82% to $9.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and ...

(Reuters) -Viatris said on Friday that its experimental ophthalmic ointment failed to meet the main goal of a late-stage study in patients with an eye condition that causes inflammation. Shares of the ...